Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Vertex Pharmaceuticals
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
Lumacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis Who Have an A455E-CFTR Mutation
To evaluate the efficacy of LUM/IVA in subjects with CF 12 years of age and older who have at least one A455E mutation.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals
MAJ Il y a 4 ans
A study to evaluate the safety and effectiveness of a quadruple drug regimen (VX-222, telaprevir, peginterferon alfa-2a and ribavirin) in treating chronic hepatitis C virus in subjects with cirrhosis who are treatment naive or nonresponders and relapsers to previous Peg- IFN/Ribavirin therapy
To evaluate the antiviral efficacy of a quadruple drug regimen (VX-222, telaprevir, Peg-IFN and RBV) in subjects with genotype 1 CHC with compensated cirrhosis, who are treatment naive or were nonresp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A study in people with Cystic Fibrosis (a rare hereditary pulmonary disease) to assess the long-term efficacy and safety of a combination of two experimental drugs
To evaluate the long term safety and tolerability of lumacaftor in combination with ivacaftor in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the for the F508del-CFTR mut...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs
To evaluate the long-term safety and tolerability of VX-509 treatment in subjects with RA on DMARD therapy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects with Genotype G551D
- Evaluate the safety and tolerability of multiple dose administrations of orally administered VX-770 given to cystic fibrosis (CF) subjects with genotype G551D.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incoporated
MAJ Il y a 4 ans
A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C. Studio di fase 3 con 2 regimi di dosaggio di Telaprevir in combinazione con Peginterferone Alfa-2a (Pegasys) e Ribavirina (Copegus) in soggetti naive con epatite C cronica 1 genotipo 1
To demonstrate the efficacy of telaprevir in combination with peginterferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-naive subjects with genotype 1 chronic hepatitis C. Dimostr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
Study of VX-509 in Rheumatoid Arthritis Subjects taking Methotrexate
To evaluate the efficacy of multiple doses of VX-509 when administered for 12 weeks in subjects with active RA on stable MTX therapy. To evaluate the safety and tolerability of multiple doses of V...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals
MAJ Il y a 4 ans
A Two-Part Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
PART A - To evaluate the short-term safety of telaprevir in combination with peginterferon alfa-2b (Peg-IFN) and ribavirin (RBV) (Peg-IFN/RBV) in treatment-naïve pediatric subjects without cirrhosis ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response with a Prior Course of Interferon Based Therapy
- To compare to control (Group A) (peginterferon alfa-2a [Peg IFN-a-2a] and ribavirin [RBV] for 48 weeks) the proportion of subjects who achieve sustained viral response (SVR, undetectable HCV RNA 24 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 when Administered Concomitantly with Methotrexate
*To evaluate the effects of 2 dosing regimens of VX-702 administered with concomitant methotrexate (MTX), and MTX alone, on the concentrations of serum and urinary biomarkers of inflammation and bone ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
Suivant